| Literature DB >> 23758810 |
Ayami Kume1, Kayo Kurotani, Masao Sato, Yuko Ejima, Ngoc Minh Pham, Akiko Nanri, Keisuke Kuwahara, Tetsuya Mizoue.
Abstract
BACKGROUND: Supplementation studies have suggested a role of n-3 polyunsaturated fatty acids (PUFAs) in homocysteine metabolism, but the evidence is limited and inconsistent among studies that measured blood levels of n-3 and n-6 PUFAs. We examined the association between blood levels of PUFAs and homocysteine in Japanese men and women.Entities:
Year: 2013 PMID: 23758810 PMCID: PMC3681585 DOI: 10.1186/1743-7075-10-41
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Characteristics of the subjects according to tertile of n-3 PUFA and n-6 PUFA in serum cholesterol ester
| | | | | | | |||
|---|---|---|---|---|---|---|---|---|
| No. of subjects | 166 | 165 | 165 | | 166 | 165 | 165 | |
| Age (y, mean ± SD) | 37.9 ± 9.3 | 41.8 ± 10.5 | 47.7 ± 9.8 | <0.001 | 47.9 ± 10.1 | 41.4 ± 10.4 | 38.1 ± 8.9 | <0.001 |
| Sex (male,%) | 52.4 | 54.6 | 68.5 | <0.001 | 79.5 | 57.0 | 38.8 | <0.001 |
| Workplace (A,%)3 | 31.3 | 31.5 | 29.7 | 0.75 | 29.5 | 31.5 | 31.5 | 0.69 |
| Body Mass Index (kg/m2, mean ± SD) | 21.9 ± 3.3 | 22.5 ± 3.9 | 23.0 ± 3.2 | 0.01 | 23.5 ± 3.5 | 22.3 ± 3.5 | 21.6 ± 3.2 | <0.001 |
| Current smoking (%) | 21.1 | 28.5 | 32.7 | 0.02 | 43.4 | 26.1 | 12.7 | <0.001 |
| Alcohol consumption (≥20 g of ethanol/d,%) | 28.9 | 40.0 | 58.2 | <0.001 | 64.5 | 35.2 | 27.3 | <0.001 |
| Occupational physical activity (sedentary,%) | 80.1 | 77.6 | 83.6 | 0.12 | 81.9 | 84.2 | 75.2 | 0.42 |
| Non-occupational physical activity (≥5 MET-h/wk,%) | 27.7 | 29.7 | 30.3 | 0.60 | 36.8 | 30.3 | 20.6 | 0.001 |
| Serum folate (ng/ml) | 3.4 (2.6, 4.9)4 | 3.8 (2.7, 5.0) | 4.3 (3.1, 5.8) | 0.002 | 3.4 (2.7, 4.7) | 3.8 (2.7, 5.7) | 4.0 (3.0, 5.3) | 0.005 |
| Dietary intake of vitamin B6 | | | | | | | | |
| (mg/1000 kcal, mean ± SD) | 0.6 ± 0.2 | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.18 | 0.6 ± 0.2 | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.28 |
| Dietary intake of vitamin B12 (μg/1000 kcal) | 3.9 (2.8, 5.0) | 4.1 (3.1, 5.2) | 5.1 (4.0, 6.2) | <0.001 | 4.8 (3.6, 6.1) | 4.3 (3.0, 5.9) | 4.0 (3.0, 5.0) | <0.001 |
Abbreviations: T Tertile, PUFA Polyunsaturated fatty acids, SD Standard deviation, MET Metabolic equivalent.
1Median percentage of n-3 PUFA or n-6 PUFA (all such values).
2P-trend values were based on the Mantel-Haenszel chi-square test for categorical variables and on linear regression analysis for continuous variables,with ordinal numbers 0–2 assigned to tertile categories of each fatty acid.
3A, workplace surveyed in July.
4Median (interquartile range) of serum folate and dietary intake of vitamin B12.
Mean serum homocysteine concentrations according to tertile of n-3 PUFA and n-6 PUFA in serum phospholipids
| PUFA | | | |
| <44.32% | 166 | 10.58 (10.13, 11.05)3 | 10.45 (10.05, 10.88) |
| 44.32–46.20% | 165 | 10.23 (9.81, 10.68) | 10.16 (9.77, 10.55) |
| ≥46.21% | 165 | 9.95 (9.52, 10.39) | 10.14 (9.75, 10.55) |
| | | 0.06 | 0.34 |
| n-6 PUFA5 | | | |
| <32.44% | 166 | 10.18 (9.72, 10.66) | 10.32 (9.90, 10.77) |
| 32.44–35.19% | 165 | 10.05 (9.63, 10.49) | 9.98 (9.61, 10.37) |
| ≥35.20% | 165 | 10.52 (10.05, 11.02) | 10.45 (10.02, 10.90) |
| | | 0.34 | 0.67 |
| LA (18:2n-6) | | | |
| <19.98% | 166 | 10.32 (9.90, 10.77) | 10.08 (9.64, 10.55) |
| 19.98–22.92% | 165 | 9.98 (9.61, 10.37) | 10.12 (9.70, 10.56) |
| ≥22.93% | 165 | 10.45 (10.02, 10.90) | 10.55 (10.09, 11.04) |
| | | 0.67 | 0.14 |
| DGLA (20:3n-6) | | | |
| <1.96% | 166 | 10.11 (9.68, 10.55) | 10.25 (9.85, 10.66) |
| 1.96–2.43% | 165 | 10.47 (10.04, 10.93) | 10.39 (9.99, 10.79) |
| ≥2.44% | 165 | 10.17 (9.74, 10.62) | 10.12 (9.71, 10.54) |
| | | 0.83 | 0.64 |
| AA (20:4n-6) | | | |
| < 9.25% | 166 | 10.30 (9.86, 10.75) | 10.29 (9.85, 10.65) |
| 9.25 –10.71% | 165 | 10.27 (9.84, 10.72) | 10.39 (10.00, 10.80) |
| ≥ 10.72% | 165 | 10.18 (9.75, 10.63) | 10.12 (9.73, 10.52) |
| | | 0.73 | 0.64 |
| n-3 PUFA5 | | | |
| <9.95% | 166 | 10.75 (10.29, 11.23) | 10.49 (10.07, 10.92) |
| 9.95–12.34% | 165 | 10.08 (9.66, 10.52) | 10.07 (9.69, 10.46) |
| ≥12.35% | 165 | 9.93 (9.50, 10.38) | 10.20 (9.79, 10.62) |
| | | 0.02 | 0.36 |
| EPA (20:5n-3) | | | |
| <1.87% | 166 | 10.76 (10.31, 11.24) | 10.56 (10.14, 10.99) |
| 1.87–2.89% | 165 | 10.10 (9.68, 10.54) | 10.12 (9.74, 10.51) |
| ≥2.90% | 165 | 9.90 (9.48, 10.34) | 10.08 (9.69, 10.49) |
| | | 0.01 | 0.12 |
| DPA (22:5n-3) | | | |
| <0.99% | 166 | 10.61 (10.15, 11.09) | 10.49 (10.08, 10.92) |
| 0.99–1.20% | 165 | 10.14 (9.72, 10.58) | 10.09 (9.71, 10.48) |
| ≥1.21% | 165 | 10.01 (9.57, 10.48) | 10.18 (9.76, 10.60) |
| | | 0.08 | 0.30 |
| DHA (22:6n-3) | | | |
| <6.84% | 166 | 10.72 (10.26, 11.19) | 10.57 (10.16, 11.00) |
| 6.84–8.25% | 165 | 10.33 (9.90, 10.77) | 10.25 (9.87, 10.64) |
| ≥8.26% | 165 | 9.73 (9.31, 10.17) | 9.94 (9.55, 10.34) |
| | 0.003 | 0.04 |
Abbreviations: AA Arachidonic acid, DGLA Dihomo-γ-linolenic acid, DHA Docosahexaenoic acid, DPA Docosapentaenoic acid, EPA Eicosapentaenoic acid, LA Linoleic acid, PUFA Polyunsaturated fatty acid.
1Adjusted for age (y, continuous), sex and workplace [A (surveyed in July) or B (surveyed in November)].
2Adjusted for age (y, continuous), sex, workplace [A (surveyed in July) or B (surveyed in November)], smoking status (non-smoker or smoker), BMI (kg/m2, continuous), alcohol consumption (non-drinker, <20 g/d or ≥20 g/d), occupational physical activity (sedentary work or active work), non-occupational physical activity (0, 0 < to <5 or ≥5 MET-h/wk), serum folate (ng/mL, continuous), vitamin B6 intake (mg/1000 kcal, continuous) and vitamin B12 intake (μg/1000 kcal, continuous).
3Geometric means (95% confidence interval) of serum homocysteine (nmol/mL).
4P-trend values were based on multiple regression analysis, with ordinal numbers 0–2 assigned to tertile categories of each fatty acid.
5N-6 PUFA is the sum of LA, DGLA, and AA; n-3 PUFA is the sum of EPA, DPA, and DHA; PUFA is the sum of n-6 and n-3 PUFA.
Mean serum homocysteine concentrations according to tertile of n-3 PUFA and n-6 PUFA in serum CE
| PUFA | | | |
| <65.27% | 166 | 10.51 (10.05, 10.99)3 | 10.40 (9.98, 10.83) |
| 65.27–68.11% | 165 | 10.20 (9.77, 10.65) | 10.11 (9.73, 10.50) |
| ≥68.12% | 165 | 10.04 (9.61, 10.49) | 10.25 (9.85, 10.66) |
| | | 0.17 | 0.66 |
| n-6 PUFA5 | | | |
| <60.77% | 166 | 10.27 (9.81, 10.75) | 10.19 (9.77, 10.62) |
| 60.77–64.19% | 165 | 10.28 (9.85, 10.73) | 10.27 (9.88, 10.66) |
| ≥64.20% | 165 | 10.20 (9.76, 10.68) | 10.30 (9.89, 10.73) |
| | | 0.86 | 0.74 |
| LA (18:2n-6) | | | |
| <52.45% | 166 | 10.20 (9.75, 10.68) | 10.21 (9.79, 10.64) |
| 52.45–56.90% | 165 | 10.27 (9.84, 10.71) | 10.23 (9.85, 10.63) |
| ≥56.91% | 165 | 10.28 (9.83, 10.75) | 10.31 (9.90, 10.75) |
| | | 0.83 | 0.74 |
| GLA (18:3n-6) | | | |
| <0.44% | 166 | 10.03 (9.61, 10.48) | 10.13 (9.74, 10.53) |
| 0.44–0.66% | 165 | 10.27 (9.84, 10.72) | 10.26 (9.88, 10.66) |
| ≥0.67% | 165 | 10.45 (10.01, 10.92) | 10.36 (9.97, 10.77) |
| | | 0.20 | 0.43 |
| DGLA (20:3n-6) | | | |
| <0.45% | 166 | 10.15 (9.71, 10.60) | 10.15 (9.75, 10.57) |
| 0.45–0.56% | 165 | 10.50 (10.06, 10.96) | 10.55 (10.16, 10.96) |
| ≥0.57% | 165 | 10.11 (9.67, 10.57) | 10.05 (9.64, 10.48) |
| | | 0.93 | 0.81 |
| AA (20:4n-6) | | | |
| <6.06% | 166 | 10.42 (9.98, 10.87) | 10.34 (9.95, 10.74) |
| 6.06–7.17% | 165 | 10.20 (9.77, 10.65) | 10.23 (9.85, 10.63) |
| ≥7.18% | 165 | 10.13 (9.71, 10.57) | 10.18 (9.79, 10.58) |
| | | 0.37 | 0.58 |
| n-3 PUFA5 | | | |
| <3.35% | 166 | 10.73 (10.27, 11.21) | 10.45 (10.04, 10.88) |
| 3.35–4.71% | 165 | 10.25 (9.82, 10.69) | 10.14 (9.75, 10.54) |
| ≥4.72% | 165 | 9.79 (9.36, 10.23) | 10.16 (9.36, 10.58) |
| | | 0.01 | 0.34 |
| ALA (18:3n-3) | | | |
| <0.56% | 167 | 10.54 (10.10, 11.00) | 10.25 (10.03, 10.48) |
| 0.56–0.67% | 166 | 10.47 (10.04, 10.92) | 10.25 (10.03, 10.47) |
| ≥0.68% | 163 | 9.75 (9.33, 10.18) | 10.25 (10.03, 10.48) |
| | | 0.02 | 0.99 |
| EPA (20:5n-3) | | | |
| <1.66% | 166 | 10.72 (10.26, 11.20) | 10.45 (10.03, 10.88) |
| 1.66–2.79% | 165 | 10.12 (9.70, 10.55) | 10.12 (9.75, 10.52) |
| ≥2.80% | 165 | 9.93 (9.50, 10.38) | 10.18 (9.77, 10.60) |
| | | 0.02 | 0.40 |
| DHA (22:6n-3) | | | |
| <1.00% | 166 | 10.73 (10.27, 11.20) | 10.49 (10.09, 10.91) |
| 1.00–1.31% | 165 | 10.09 (9.67, 10.53) | 10.05 (9.68, 10.44) |
| ≥1.32% | 165 | 9.95 (9.52, 10.40) | 10.21 (9.81, 10.63) |
| | 0.02 | 0.34 |
Abbreviations: AA Arachidonic acid, ALA A-linolenic acid, CE Cholesterol ester, DGLA Dihomo-γ-linolenic acid, DHA Docosahexaenoic acid, EPA Eicosapentaenoic acid, GLA γ-linolenic acid, LA Linoleic acid, PUFA Polyunsaturated fatty acid.
1Adjusted for age (y, continuous), sex and workplace [A (surveyed in July) or B (surveyed in November)].
2Adjusted for age (y, continuous), sex, workplace [A (surveyed in July) or B (surveyed in November)], smoking status (non-smoker or smoker), BMI (kg/m2, continuous), alcohol consumption (non-drinker, <20 g/d or ≥20 g/d), occupational physical activity (sedentary work or active work), non-occupational physical activity (0, 0 < to <5 or ≥5 MET-h/wk), serum folate (ng/mL, continuous), vitamin B6 intake (mg, continuous) and vitamin B12 intake (μg/1000 kcal, continuous).
3Geometric means (95% confidence interval) of serum homocysteine (nmol/mL).
4P-trend values were based on multiple regression analysis, with ordinal numbers 0–2 assigned to tertile categories of each fatty acid.
5N-6 PUFA is the sum of LA, GLA, DGLA, and AA; n-3 PUFA is the sum of ALA, EPA, and DHA; PUFA is the sum of n-6 and n-3 PUFA.